From PCOS to PMOS: Why One Letter Changes Everything

If you have ever been told you have polycystic ovary syndrome — or if you suspect you might — you may already know the frustration of a name that doesn’t quite fit. Maybe you were told you have “cysts on your ovaries,” only to discover on further examination that you don’t have classic cysts at all. Maybe your primary complaint was fatigue, weight gain, or a skin condition, and yet the conversation kept circling back to your fertility. You were not imagining the disconnect. The name was the problem.

On May 12, 2026, that name officially changed. After more than a decade of research, global surveys involving over 22,000 patients and clinicians, and a landmark consensus published in The Lancet, polycystic ovary syndrome — PCOS — has been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. It is a change that looks modest on paper but carries enormous implications for how the condition is understood, diagnosed, and treated worldwide.

FORMER NAME PCOS Polycystic Ovary Syndrome — implied cysts were the central feature, obscuring hormonal and metabolic complexity.

NEW NAME · 2026 PMOS Polyendocrine Metabolic Ovarian Syndrome — reflects a multi-system condition involving hormones, metabolism, and the ovaries together.

The Problem With “Cysts”

The word “polycystic” means “many cysts,” and for decades that single word sent both patients and doctors down the wrong path. In reality, what appears on an ultrasound in this condition is not true pathological cysts but rather clusters of small, immature follicles — tiny fluid-filled sacs that are a normal part of the ovary’s cycle but accumulate when ovulation is disrupted. They are a symptom of a hormonal imbalance, not the disease itself.

This distinction matters enormously. A woman who came to her doctor with irregular periods, acne, thinning hair, and difficulty managing her weight could be dismissed if her ultrasound didn’t show the expected cystic pattern. The WHO estimates that up to 70% of women who have this condition remain undiagnosed — a staggering figure that reflects, at least in part, how misleading the name has been.

1 in 8

women of reproductive age are affected worldwide — over 170 million people — yet most remain undiagnosed

What PMOS Actually Is: A Whole-Body Story

The new name — Polyendocrine Metabolic Ovarian Syndrome — contains three key ideas, and each one is doing important scientific work.

“Polyendocrine” means that multiple glands and hormones are involved. The condition is not simply an ovarian disorder; it is a systemic hormonal disruption. The ovaries, adrenal glands, pituitary gland, and pancreas all interact in ways that amplify each other’s dysregulation. At its core, PMOS involves elevated androgens — hormones like testosterone that are present in all women but produced in excess here — which disrupt the normal signalling that tells the ovary when to release an egg each month.

“Metabolic” acknowledges what has been known for decades but rarely centred in clinical care: the majority of people with PMOS have some degree of insulin resistance. This means the body’s cells don’t respond efficiently to insulin, the hormone that helps glucose enter cells for energy. The pancreas compensates by producing more insulin, and high insulin levels then signal the ovaries to produce more androgens. It is a cycle — hormones driving metabolism driving hormones — and it explains why PMOS is linked to type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

“Ovarian” preserves the centrality of the ovaries — not because ovarian cysts define the condition, but because the ovaries are where much of the hormonal disruption plays out visibly and measurably. The follicular development that stalls, the irregular ovulation, the hormonal environment within the ovary itself — these are real and important features of PMOS, just not the only ones.

“For too long, the name reduced a complex, long-term hormonal disorder to a misunderstanding about cysts and a focus on ovaries. This contributed to missed diagnoses and inadequate treatment.”

— Endocrine Society statement, May 2026

Genetics: Born Predisposed

One of the most important shifts embedded in the new name is the implicit acknowledgment that PMOS is not a lifestyle disease or a product of poor choices. It has a strong genetic basis. Studies in twins have shown that if one identical twin has PMOS, the other is highly likely to develop it as well. Family clustering is common; daughters of women with PMOS are at significantly elevated risk.

Genome-wide association studies have identified dozens of gene regions associated with PMOS risk. These include genes involved in insulin signalling pathways, androgen receptor sensitivity, follicle-stimulating hormone (FSH) activity, and inflammation regulation. In other words, the condition is woven into the genetic architecture of how a woman’s hormonal system is built. It is not something that happens to someone; it is something they are born predisposed to. This genetic framing changes the conversation around treatment — rather than placing the burden entirely on weight loss or lifestyle change, it opens the door to understanding that metabolic intervention, hormonal management, and long-term care are all legitimate medical responses to a medical condition.

The Metabolic Markers That Have Been Overlooked

If PMOS is diagnosed with metabolic complexity in mind, the clinical picture changes dramatically. A thorough evaluation should include markers that are often skipped in a standard gynaecological workup:

KEY MARKERS NOW CENTRAL TO PMOS DIAGNOSIS & CARE

→  Fasting insulin and glucose: to assess insulin resistance, often present even in women of normal weight

→  Total and free testosterone, DHEAS, androstenedione: to map the androgen excess driving symptoms

→  LH/FSH ratio: often elevated, indicating disturbed pituitary-ovarian signalling

→  Anti-Müllerian hormone (AMH): a sensitive marker of ovarian follicle pool, elevated in PMOS

→  Lipid panel: HDL often low, triglycerides often high, increasing cardiovascular risk

→  Blood pressure and inflammatory markers: CRP, interleukin-6, reflecting systemic low-grade inflammation

→  Mental health screening: depression and anxiety are two to three times more prevalent in PMOS

Across the Reproductive Lifespan — and Beyond

One of the most quietly transformative aspects of the renaming is how it frames PMOS across a woman’s entire life, not just her childbearing years. The old name made it sound like a fertility problem. The new one signals a lifelong hormonal-metabolic condition that deserves attention in adolescence, the reproductive years, and after menopause.

In adolescence, PMOS is notoriously difficult to diagnose — many of its features are considered normal in the first years after puberty. But early identification matters, because insulin resistance and elevated androgens in teenage girls with PMOS can set the stage for metabolic disease decades later. The new name and updated clinical guidelines explicitly bring pediatric endocrinologists into the diagnostic conversation.

During reproductive years, PMOS affects fertility through irregular or absent ovulation, but fertility is only part of the story. Women with PMOS who become pregnant face higher rates of gestational diabetes, pre-eclampsia, and preterm birth — risks that are entirely linked to the metabolic features of the condition and that improve with proper management.

After menopause, women with a history of PMOS carry elevated risk of type 2 diabetes and cardiovascular disease. Yet the condition has historically been considered resolved once periods stop. It is not. The metabolic underpinnings persist, and long-term cardiometabolic monitoring is now considered essential.

Why the Name Change Was Necessary — And Long Overdue

The consensus process that produced the new name was extraordinary in scope. Led by Professor Helena Teede at Monash University in Australia, it involved 56 patient and professional organisations, iterative workshops across all world regions, and a total of over 22,000 responses from patients, clinicians, and researchers. The process took 14 years from the first serious proposal to the final vote.

A medical name is not merely a label — it is a framework that determines which specialists see a patient, which symptoms are taken seriously, which research gets funded, and which treatments are offered. The name PCOS had, over decades, funnelled women toward gynaecologists when they also needed endocrinologists, toward fertility clinics when they also needed cardiologists, and toward conversations about their periods when they also needed conversations about their insulin. The new name is a correction of that course.

“Renaming this condition is more than semantics; it’s about finally recognising the full reality of what patients experience.”

— Dr. Melanie Cree, MD, PhD, University of Colorado Anschutz

What This Means for You

If you have been diagnosed with PCOS — now PMOS — the science that has always described your experience has not changed. Your symptoms are real. Your biology is real. What has changed is that medicine is finally naming it correctly, and that name will, over time, reshape the care you receive.

Expect clinical guidelines to be updated. Expect the conversation with your doctor to broaden — from reproductive symptoms toward metabolic health, mental wellbeing, skin, and long-term cardiovascular risk. Expect research funding to follow the new framing, opening investigations into genetic therapies, metabolic interventions, and precision-medicine approaches that treat PMOS as the complex, multi-system condition it has always been.

Reference:

• Teede H, Khomami M, Morman R et al., Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 2026.